Editas Medicine Inc (EDIT) Stake Raised by Chevy Chase Trust Holdings Inc.
Chevy Chase Trust Holdings Inc. grew its position in Editas Medicine Inc (NASDAQ:EDIT) by 13.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 448,148 shares of the company’s stock after acquiring an additional 54,850 shares during the quarter. Chevy Chase Trust Holdings Inc. owned about 0.95% of Editas Medicine worth $16,057,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of EDIT. Federated Investors Inc. PA increased its stake in Editas Medicine by 677.7% in the 1st quarter. Federated Investors Inc. PA now owns 255,100 shares of the company’s stock worth $8,457,000 after buying an additional 222,300 shares during the period. BlackRock Inc. increased its stake in Editas Medicine by 7.1% in the 1st quarter. BlackRock Inc. now owns 2,863,624 shares of the company’s stock worth $94,930,000 after buying an additional 191,068 shares during the period. Handelsbanken Fonder AB purchased a new position in Editas Medicine in the 2nd quarter worth about $4,300,000. Elmwood Wealth Management Inc. purchased a new position in Editas Medicine in the 1st quarter worth about $3,874,000. Finally, UBS Group AG increased its stake in Editas Medicine by 92.7% in the 1st quarter. UBS Group AG now owns 214,038 shares of the company’s stock worth $7,096,000 after buying an additional 102,947 shares during the period. 65.77% of the stock is currently owned by institutional investors.
Shares of Editas Medicine stock opened at $28.66 on Friday. The company has a current ratio of 11.71, a quick ratio of 11.71 and a debt-to-equity ratio of 0.13. Editas Medicine Inc has a 1 year low of $17.35 and a 1 year high of $45.02.
In other Editas Medicine news, insider Katrine Bosley sold 8,333 shares of the stock in a transaction dated Wednesday, August 1st. The shares were sold at an average price of $29.55, for a total transaction of $246,240.15. Following the transaction, the insider now directly owns 1,279,066 shares in the company, valued at approximately $37,796,400.30. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jessica Hopfield bought 6,700 shares of the company’s stock in a transaction on Thursday, May 17th. The shares were acquired at an average price of $37.28 per share, for a total transaction of $249,776.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at $372,800. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 82,999 shares of company stock worth $2,992,109. 5.20% of the stock is owned by company insiders.
EDIT has been the topic of several recent analyst reports. BidaskClub raised shares of Editas Medicine from a “hold” rating to a “buy” rating in a research note on Friday, April 13th. ValuEngine raised shares of Editas Medicine from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. Zacks Investment Research raised shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research note on Tuesday, May 15th. Chardan Capital reduced their price target on shares of Editas Medicine from $72.50 to $55.00 and set a “buy” rating on the stock in a research note on Tuesday, May 15th. Finally, JPMorgan Chase & Co. set a $36.00 price target on shares of Editas Medicine and gave the stock a “hold” rating in a research note on Monday. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the stock. Editas Medicine has an average rating of “Hold” and a consensus price target of $47.43.
Editas Medicine Company Profile
Editas Medicine, Inc operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.
Read More: What does relative strength index mean?
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.